{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:21Z","timestamp":1792057701451,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Glioblastoma (GBM) exhibits extensive metabolic reprogramming, including glucose and glutamine (Gln) addiction, with Gln being converted into glutamate by glutaminase, encoded by the\n                      <jats:italic>GLS<\/jats:italic>\n                      and\n                      <jats:italic>GLS2<\/jats:italic>\n                      genes. GLS2 acts as a context-dependent tumor suppressor, although the underlying mechanisms remain poorly understood. GLS2 is silenced in GBM, and we previously showed that its re-expression modulates pyruvate dehydrogenase (PDH) activity and tricarboxylic acid cycle (TCAC) metabolism, suggesting a distinct metabolic rewiring associated with its tumor-suppressive function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>LN229 and T98G GBM cell lines were used as experimental models. Metabolomic profiling by liquid chromatography-mass spectrometry was performed to compare changes in central metabolic pathways following GLS2 or GLS overexpression. Glutaminase and PDH enzymatic activities were measured, and Western blotting was performed to assess GLS, GLS2, and PDHA1 protein levels and PDHA1 phosphorylation. A Seahorse analyzer was employed to quantify real-time ATP production derived from glycolysis and oxidative phosphorylation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overexpression of GLS2, but not GLS, in LN229 cells caused the accumulation of TCAC-related metabolites, except for citrate, whose depletion is attributed to GLS2\u2019s effect on PDH phosphorylation, causing reduced PDH activity. This was accompanied by decreased levels of several acyl-carnitines. Furthermore, GLS2 induced the accumulation of glucose\/fructose, while reducing levels of glucose-6-phosphate and pentose-phosphates, consistent with altered glycolysis. GLS2 also diminished the ATP\/AMP ratio, confirmed by a reduced ATP synthesis rate, particularly glycolytic ATP, whereas mitochondrial ATP production remained unaltered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLS2 exerts an isoenzyme-specific effect on Gln and glucose metabolism in GBM, likely modulating the glycolysis\/pentose-phosphate pathway (PPP)-TCAC-axis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-026-00908-9","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:38:03Z","timestamp":1792042683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLS2 reshapes glycolytic metabolism and bioenergetic homeostasis in glioblastoma cells"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-047X","authenticated-orcid":false,"given":"Juan","family":"De Los Santos-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-9884","authenticated-orcid":false,"given":"Jos\u00e9 A.","family":"Campos-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-3361","authenticated-orcid":false,"given":"Jessica","family":"Sudderth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7413-6460","authenticated-orcid":false,"given":"Lauren G.","family":"Zacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-4532","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Santos Patricio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9431-163X","authenticated-orcid":false,"given":"Francisco J.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-3963","authenticated-orcid":false,"given":"Javier","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-8243","authenticated-orcid":false,"given":"Thomas P.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2705-7432","authenticated-orcid":false,"given":"Ralph J.","family":"DeBerardinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-1993","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Mat\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"908_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/onc.2009.358","volume":"29","author":"RJ DeBerardinis","year":"2010","unstructured":"DeBerardinis RJ, Cheng T. Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313\u201324. https:\/\/doi.org\/10.1038\/onc.2009.358.","journal-title":"Oncogene"},{"key":"908_CR2","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200.","journal-title":"Sci Adv"},{"key":"908_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-319-45096-4_6","volume":"13","author":"J M\u00e1rquez","year":"2016","unstructured":"M\u00e1rquez J, Mat\u00e9s JM, Campos-Sandoval JA, Glutaminases. Adv Neurobiol. 2016;13:133\u201371. https:\/\/doi.org\/10.1007\/978-3-319-45096-4_6.","journal-title":"Adv Neurobiol"},{"key":"908_CR4","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/JCI69600","volume":"123","author":"CT Hensley","year":"2013","unstructured":"Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678\u201384. https:\/\/doi.org\/10.1172\/JCI69600.","journal-title":"J Clin Invest"},{"issue":"32","key":"908_CR5","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.2174\/0929867326666190416165004","volume":"27","author":"JM Mat\u00e9s","year":"2020","unstructured":"Mat\u00e9s JM, Campos-Sandoval JA, de Los Santos-Jim\u00e9nez J, Segura JA, Alonso FJ, M\u00e1rquez J. Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes. Curr Med Chem. 2020;27(32):5317\u201339. https:\/\/doi.org\/10.2174\/0929867326666190416165004.","journal-title":"Curr Med Chem"},{"key":"908_CR6","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.3390\/cancers15235566","volume":"15","author":"J Buczkowska","year":"2023","unstructured":"Buczkowska J, Szeliga M. Two Faces of Glutaminase GLS2 in Carcinogenesis. Cancers (Basel). 2023;15:5566. https:\/\/doi.org\/10.3390\/cancers15235566.","journal-title":"Cancers (Basel)"},{"key":"908_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s12672-026-04618-9","volume":"17","author":"W Liu","year":"2026","unstructured":"Liu W, Yan Q, Wu QN, Zhi FH, Luo HH, Lei YY, et al. Characterization of tumour microenvironment in thymic epithelial tumours of different histological subtypes. Discov Oncol. 2026;17:466. https:\/\/doi.org\/10.1007\/s12672-026-04618-9.","journal-title":"Discov Oncol"},{"key":"908_CR8","doi-asserted-by":"publisher","first-page":"502","DOI":"10.20892\/j.issn.2095-3941.2024.0398","volume":"22","author":"P Wang","year":"2025","unstructured":"Wang P, Du X, Han Z, Zhong J, Yuan J, Jiang L, et al. Nuclear PHGDH regulates macrophage polarization through transcriptional repression of GLUD1 and GLS2 in breast cancer. Cancer Biol Med. 2025;22:502\u201324. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0398.","journal-title":"Cancer Biol Med"},{"key":"908_CR9","doi-asserted-by":"publisher","first-page":"189182","DOI":"10.1016\/j.bbcan.2024.189182","volume":"1879","author":"RK Veeramachaneni","year":"2024","unstructured":"Veeramachaneni RK, Suter RK, Rowland E, Jermakowicz A, Ayad NG. Glutaminase 2 as a therapeutic target in glioblastoma. Biochim Biophys Acta Rev Cancer. 2024;1879:189182. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189182.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"908_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/glia.20825","volume":"57","author":"M Szeliga","year":"2009","unstructured":"Szeliga M, Obara-Michlewska M, Matyja E, \u0141azarczyk M, Lobo C, Hilgier W, et al. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. GLIA. 2009;57:1014\u201323. https:\/\/doi.org\/10.1002\/glia.20825.","journal-title":"GLIA"},{"key":"908_CR11","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.3390\/cancers11101610","volume":"11","author":"E Ramirez-Pe\u00f1a","year":"2019","unstructured":"Ramirez-Pe\u00f1a E, Arnold J, Shivakumar V, Joseph R, Vidhya Vijay G, den Hollander P, et al. The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression. Cancers (Basel). 2019;11:1610. https:\/\/doi.org\/10.3390\/cancers11101610.","journal-title":"Cancers (Basel)"},{"key":"908_CR12","doi-asserted-by":"publisher","first-page":"115596","DOI":"10.1016\/j.celrep.2025.115596","volume":"44","author":"S Udutha","year":"2025","unstructured":"Udutha S, Taglang C, Batsios G, Gillespie AM, Tran M, Hoeve JT, et al. Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma. Cell Rep. 2025;44:115596. https:\/\/doi.org\/10.1016\/j.celrep.2025.115596.","journal-title":"Cell Rep"},{"key":"908_CR13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1172\/JCI78239","volume":"125","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 2015;125:1591\u2013602. https:\/\/doi.org\/10.1172\/JCI78239.","journal-title":"J Clin Invest"},{"key":"908_CR14","doi-asserted-by":"publisher","first-page":"1712576","DOI":"10.3389\/fonc.2025.1712576","volume":"15","author":"J Chung","year":"2025","unstructured":"Chung J, Saad J, Kafri A, Rossignol J, Verbrugge M, Bakke J. Metabolism of glioblastoma: a review of metabolic adaptations and metabolic therapeutic interventions. Front Oncol. 2025;15:1712576. https:\/\/doi.org\/10.3389\/fonc.2025.1712576.","journal-title":"Front Oncol"},{"key":"908_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers15020531","volume":"15","author":"J De Los Santos-Jim\u00e9nez","year":"2023","unstructured":"De Los Santos-Jim\u00e9nez J, Rosales T, Ko B, Campos-Sandoval JA, Alonso FJ, M\u00e1rquez J, et al. Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines. Cancers (Basel). 2023;15:531. https:\/\/doi.org\/10.3390\/cancers15020531.","journal-title":"Cancers (Basel)"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/ijms26010427","volume":"26","author":"J De Los Santos-Jim\u00e9nez","year":"2025","unstructured":"De Los Santos-Jim\u00e9nez J, Campos-Sandoval JA, Rosales T, Ko B, Alonso FJ, M\u00e1rquez J, et al. Glutaminase-2 Expression Induces Metabolic Changes and Regulates Pyruvate Dehydrogenase Activity in Glioblastoma Cells. Int J Mol Sci. 2025;26:427. https:\/\/doi.org\/10.3390\/ijms26010427.","journal-title":"Int J Mol Sci"},{"key":"908_CR17","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.3390\/cancers14153769","volume":"14","author":"CM Larrieu","year":"2022","unstructured":"Larrieu CM, Storevik S, Guyon J, Pagano Zottola AC, Bouchez CL, et al. Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development. Cancers (Basel). 2022;14:3769. https:\/\/doi.org\/10.3390\/cancers14153769.","journal-title":"Cancers (Basel)"},{"key":"908_CR18","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.3390\/ijms231710037","volume":"23","author":"A Fukushi","year":"2022","unstructured":"Fukushi A, Kim HD, Chang YC, Kim CH. Revisited Metabolic Control and Reprogramming Cancers by Means of the Warburg Effect in Tumor Cells. Int J Mol Sci. 2022;23:10037. https:\/\/doi.org\/10.3390\/ijms231710037.","journal-title":"Int J Mol Sci"},{"key":"908_CR19","doi-asserted-by":"publisher","first-page":"115166","DOI":"10.1016\/j.ejmech.2023.115166","volume":"249","author":"H Lin","year":"2023","unstructured":"Lin H, Han H, Yang M, Wen Z, Chen Q, Ma Y, et al. PKM2\/PDK1 dual-targeted shikonin derivatives restore the sensitivity of EGFR-mutated NSCLC cells to gefitinib by remodeling glucose metabolism. Eur J Med Chem. 2023;249:115166. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115166.","journal-title":"Eur J Med Chem"},{"key":"908_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12929-021-00712-y","volume":"28","author":"J De Los Santos-Jim\u00e9nez","year":"2021","unstructured":"De Los Santos-Jim\u00e9nez J, Campos-Sandoval JA, M\u00e1rquez-Torres C, Urbano-Polo N, Br\u00f8ndegaard D, Mart\u00edn-Rufi\u00e1n M, et al. Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells. J Biomed Sci. 2021;28:14. https:\/\/doi.org\/10.1186\/s12929-021-00712-y.","journal-title":"J Biomed Sci"},{"key":"908_CR21","doi-asserted-by":"publisher","first-page":"e61980","DOI":"10.7554\/eLife.61980","volume":"10","author":"AW DeVilbiss","year":"2021","unstructured":"DeVilbiss AW, Zhao Z, Martin-Sandoval MS, Ubellacker JM, Tasdogan A, Agathocleous M, et al. Metabolomic profiling of rare cell populations isolated by flow cytometry from tissues. Elife. 2021;10:e61980. https:\/\/doi.org\/10.7554\/eLife.61980.","journal-title":"Elife"},{"key":"908_CR22","doi-asserted-by":"publisher","first-page":"e2120617119","DOI":"10.1073\/pnas.2120617119","volume":"119","author":"AB Aurora","year":"2022","unstructured":"Aurora AB, Khivansara V, Leach A, Gill JG, Martin-Sandoval M, Yang C, et al. Loss of glucose 6-phosphate dehydrogenase function increases oxidative stress and glutaminolysis in metastasizing melanoma cells. Proc Natl Acad Sci U S A. 2022;119:e2120617119. https:\/\/doi.org\/10.1073\/pnas.2120617119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"908_CR23","doi-asserted-by":"publisher","first-page":"F140","DOI":"10.1152\/ajprenal.00217.2006","volume":"292","author":"NP Curthoys","year":"2007","unstructured":"Curthoys NP, Taylor L, Hoffert JD, Knepper MA. Proteomic analysis of the adaptive response of rat renal proximal tubules to metabolic acidosis. Am J Physiol Ren Physiol. 2007;292:F140\u20137. https:\/\/doi.org\/10.1152\/ajprenal.00217.2006.","journal-title":"Am J Physiol Ren Physiol"},{"key":"908_CR24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/mc.22372","volume":"55","author":"M Szeliga","year":"2016","unstructured":"Szeliga M, Bogaci\u0144ska-Kara\u015b M, Ku\u017amicz K, Rola R, Albrecht J. Downregulation of GLS2 in glioblastoma cells is related to DNA hypermethylation but not to the p53 status. Mol Carcinog. 2016;55:1309\u201316. https:\/\/doi.org\/10.1002\/mc.22372.","journal-title":"Mol Carcinog"},{"key":"908_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00109-013-1105-2","volume":"92","author":"M Mart\u00edn-Rufi\u00e1n","year":"2014","unstructured":"Mart\u00edn-Rufi\u00e1n M, Nascimento-Gomes R, Higuero A, Crisma AR, Campos-Sandoval JA, G\u00f3mez-Garc\u00eda MC, et al. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med (Berl). 2014;92:277\u201390. https:\/\/doi.org\/10.1007\/s00109-013-1105-2.","journal-title":"J Mol Med (Berl)"},{"key":"908_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","volume":"18","author":"JB Wang","year":"2010","unstructured":"Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18:207\u201319. https:\/\/doi.org\/10.1016\/j.ccr.2010.08.009.","journal-title":"Cancer Cell"},{"key":"908_CR27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","volume":"13","author":"MI Gross","year":"2014","unstructured":"Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890\u2013901. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0870.","journal-title":"Mol Cancer Ther"},{"key":"908_CR28","doi-asserted-by":"publisher","first-page":"7455","DOI":"10.1073\/pnas.1001006107","volume":"107","author":"W Hu","year":"2010","unstructured":"Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010;107:7455\u201360. https:\/\/doi.org\/10.1073\/pnas.1001006107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"908_CR29","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/0008-5472.CAN-21-3914","volume":"82","author":"S Suzuki","year":"2022","unstructured":"Suzuki S, Venkatesh D, Kanda H, Nakayama A, Hosokawa H, Lee E, et al. GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma. Cancer Res. 2022;82:3209\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3914.","journal-title":"Cancer Res"},{"key":"908_CR30","doi-asserted-by":"publisher","first-page":"37028","DOI":"10.1038\/s41598-025-20528-2","volume":"15","author":"M Spada","year":"2025","unstructured":"Spada M, Piras C, Leoni VP, Casula M, Simbula G, Noto A, et al. Glutaminase inhibitor CB-839 causes metabolic adjustments in colorectal cancer cells. Sci Rep. 2025;15:37028. https:\/\/doi.org\/10.1038\/s41598-025-20528-2.","journal-title":"Sci Rep"},{"key":"908_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/cdd.2014.173","volume":"22","author":"DJ Roberts","year":"2015","unstructured":"Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22:248\u201357. https:\/\/doi.org\/10.1038\/cdd.2014.173.","journal-title":"Cell Death Differ"},{"key":"908_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762\u20135. https:\/\/doi.org\/10.1038\/nature07823.","journal-title":"Nature"},{"key":"908_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43:11\u201321. https:\/\/doi.org\/10.1016\/j.semcdb.2015.08.003.","journal-title":"Semin Cell Dev Biol"},{"key":"908_CR34","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrc.2016.71","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619\u201334. https:\/\/doi.org\/10.1038\/nrc.2016.71.","journal-title":"Nat Rev Cancer"},{"key":"908_CR35","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.addr.2009.06.009","volume":"61","author":"MG Rosca","year":"2009","unstructured":"Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009;61:1332\u201342. https:\/\/doi.org\/10.1016\/j.addr.2009.06.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"908_CR36","doi-asserted-by":"publisher","first-page":"100941","DOI":"10.1016\/j.molmet.2020.01.005","volume":"38","author":"S Trefely","year":"2020","unstructured":"Trefely S, Lovell CD, Snyder NW, Wellen KE. Compartmentalised acyl-CoA metabolism and roles in chromatin regulation. Mol Metab. 2020;38:100941. https:\/\/doi.org\/10.1016\/j.molmet.2020.01.005.","journal-title":"Mol Metab"},{"key":"908_CR37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ymgme.2019.05.002","volume":"128","author":"H Yang","year":"2019","unstructured":"Yang H, Zhao C, Tang MC, Wang Y, Wang SP, Allard P, et al. Inborn errors of mitochondrial acyl-coenzyme a metabolism: acyl-CoA biology meets the clinic. Mol Genet Metab. 2019;128:30\u201344. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.002.","journal-title":"Mol Genet Metab"},{"key":"908_CR38","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/pharmrev.121.000408","volume":"74","author":"M Dambrova","year":"2022","unstructured":"Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, et al. Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol Rev. 2022;74:506\u201351. https:\/\/doi.org\/10.1124\/pharmrev.121.000408.","journal-title":"Pharmacol Rev"},{"key":"908_CR39","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368:eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"key":"908_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/antiox13060745","volume":"13","author":"J De Los Santos-Jim\u00e9nez","year":"2024","unstructured":"De Los Santos-Jim\u00e9nez J, Campos-Sandoval JA, Alonso FJ, M\u00e1rquez J, Mat\u00e9s JM. GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells. Antioxid (Basel). 2024;13:745. https:\/\/doi.org\/10.3390\/antiox13060745.","journal-title":"Antioxid (Basel)"},{"key":"908_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12031-024-02201-x","volume":"74","author":"H Fu","year":"2024","unstructured":"Fu H, Wu S, Shen H, Luo K, Huang Z, Lu N, et al. Glutamine Metabolism Heterogeneity in Glioblastoma Unveils an Innovative Combination Therapy Strategy. J Mol Neurosci. 2024;74:52. https:\/\/doi.org\/10.1007\/s12031-024-02201-x.","journal-title":"J Mol Neurosci"},{"key":"908_CR42","doi-asserted-by":"publisher","first-page":"e2412507","DOI":"10.1002\/advs.202412507","volume":"12","author":"Y Guo","year":"2025","unstructured":"Guo Y, Jiang T, Liang S, Wang A, Li J, Jia Y, et al. Immunostimulatory Hydrogel with Synergistic Blockage of Glutamine Metabolism and Chemodynamic Therapy for Postoperative Management of Glioblastoma. Adv Sci (Weinh). 2025;12:e2412507. https:\/\/doi.org\/10.1002\/advs.202412507.","journal-title":"Adv Sci (Weinh)"},{"key":"908_CR43","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41417-025-00906-8","volume":"32","author":"F Martins","year":"2025","unstructured":"Martins F, Arada R, Barros H, Matos P, Ramalho J, Ce\u00f1a V, et al. Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM). Cancer Gene Ther. 2025;32:690\u2013705. https:\/\/doi.org\/10.1038\/s41417-025-00906-8.","journal-title":"Cancer Gene Ther"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00908-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00908-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00908-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:22:02Z","timestamp":1792056122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00908-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":43,"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00908-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, as no patient subjects were included in this study.","order":1,"name":"Ethics","label":"Ethics consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.J.D. is an adviser for Illumina, General Metabolics, Vida Ventures, Faeth Therapeutics, and Alterris Oncology, and is a founder and adviser at Atavistik Bioscience. The funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to publish the results.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}